Valuation: AP Biosciences, Inc.

Market Cap 1.19TCr 37Cr 33Cr 30Cr 28Cr 52Cr 3.48TCr 53Cr 366.13Cr 143.25Cr 1.82TCr 137.88Cr 134.96Cr 5.81TCr P/E 2024
-8.86x
P/E 2025 -34.4x
Enterprise Value 1.08TCr 33Cr 30Cr 28Cr 25Cr 47Cr 3.15TCr 48Cr 331.93Cr 129.87Cr 1.65TCr 125Cr 122.35Cr 5.27TCr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
52.82%
Yield 2024 *
-
Yield 2025 -
1 day-0.41%
1 week-8.27%
Current month-17.85%
1 month+11.42%
3 months+8.93%
6 months-37.11%
Current year-32.22%
1 week 120
Extreme 120
133.5
1 month 114
Extreme 114
149
Current year 86.1
Extreme 86.1
236
1 year 86.1
Extreme 86.1
236
3 years 36.3
Extreme 36.3
236
5 years 36.3
Extreme 36.3
236
10 years 36.3
Extreme 36.3
236
Manager TitleAgeSince
Chief Executive Officer - 27/05/2013
Director of Finance/CFO - 18/10/2022
Chief Administrative Officer - 18/10/2022
Director TitleAgeSince
Director/Board Member - 09/11/2022
Director/Board Member - 04/06/2019
Director/Board Member - 04/06/2021
Change 5-day change 1-year change 3-year change Capi.($)
-0.41%-8.27%+19.61%+131.50% 37Cr
+0.21%-4.63%+55.34%+71.32% 6.9TCr
-0.50%+3.68%+6.19%+60.68% 5.31TCr
-0.76%+4.82%+9.41%+40.77% 5.08TCr
+3.45%+4.70%+33.44%+35.96% 4.46TCr
-2.20%+0.61%+281.88%+532.76% 4.06TCr
+6.43%+6.84%+18.32%+109.23% 4.25TCr
+1.28%+1.39%+11.69%+45.10% 3.09TCr
-0.90%-10.49%+31.48%-1.63% 2.54TCr
+1.74%-2.02%-13.55%-12.92% 2.27TCr
Average +0.84%+0.58%+45.38%+101.28% 3.8TCr
Weighted average by Cap. +0.92%+2.32%+50.50%+103.11%

Financials

2024 2025
Net sales - -
Net income -42Cr -1.31Cr -1.17Cr -1.08Cr -98.5L -1.85Cr -123.63Cr -1.89Cr -13Cr -5.09Cr -65Cr -4.9Cr -4.79Cr -206.42Cr -44Cr -1.37Cr -1.23Cr -1.14Cr -1.04Cr -1.95Cr -130.07Cr -1.98Cr -14Cr -5.35Cr -68Cr -5.15Cr -5.04Cr -217.17Cr
Net Debt -147.07Cr -4.54Cr -4.05Cr -3.77Cr -3.43Cr -6.45Cr -430.12Cr -6.56Cr -45Cr -18Cr -224.42Cr -17Cr -17Cr -718.12Cr -111.14Cr -3.43Cr -3.06Cr -2.85Cr -2.59Cr -4.87Cr -325.03Cr -4.96Cr -34Cr -13Cr -169.58Cr -13Cr -13Cr -542.66Cr
Projected Income Statement - Annual - AP Biosciences, Inc.
Logo AP Biosciences, Inc.
AP Biosciences Inc is a Taiwan-based company mainly engaged in the research and development of protein drugs and antibody drugs. The Company develops early candidate drugs and preclinical trials, and develops different monoclonal or bispecific antibody drugs for potential targets, mechanisms of action, and disease characteristics through drug design and existing technology platforms. The Company's technology platform and bispecific protein drug research and development projects include IBI302-anti-vascular endothelial growth factor (VEGF) and anti-complement bifunctional recombinant protein, OmniMab fully human antibody library, AP505-PD-L1 x VEGF bispecific antibody, target-directed T cell activation 3T platform (T-cube), AP203-PD-L1 x CD137 fully human bispecific antibody, and others.
Employees
-
Date Price Change Volume
15/26/15 NT$122.00 -0.41% 2,94,644
14/26/14 NT$122.50 -0.81% 1,61,757
13/26/13 NT$123.50 -1.59% 2,62,154
12/26/12 NT$125.50 -5.64% 4,36,227
08/26/08 NT$133.00 -5.00% 7,92,852
  1. Stock Market
  2. Stocks
  3. 6945 Stock